153 related articles for article (PubMed ID: 37337737)
21. Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis.
Jeon WJ; Nguyen J; Castillo DR; Park K; Brothers J; Nguyen A; Mirshahidi H
J Oncol Pharm Pract; 2023 Jul; 29(5):1264-1267. PubMed ID: 36648206
[TBL] [Abstract][Full Text] [Related]
22. Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.
Fukihara J; Sakamoto K; Koyama J; Ito T; Iwano S; Morise M; Ogawa M; Kondoh Y; Kimura T; Hashimoto N; Hasegawa Y
Clin Lung Cancer; 2019 Nov; 20(6):442-450.e4. PubMed ID: 31446020
[TBL] [Abstract][Full Text] [Related]
23. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
[TBL] [Abstract][Full Text] [Related]
24. Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.
Wang Y; Wang Y; Yu J; Meng X
Front Immunol; 2022; 13():998516. PubMed ID: 36189237
[TBL] [Abstract][Full Text] [Related]
25. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study.
Fujimoto D; Miura S; Yoshimura K; Wakuda K; Oya Y; Yokoyama T; Yokoi T; Asao T; Tamiya M; Nakamura A; Yoshioka H; Haratani K; Teraoka S; Tokito T; Murakami S; Tamiya A; Itoh S; Yokouchi H; Watanabe S; Yamaguchi O; Tomii K; Yamamoto N
Eur J Cancer; 2021 Jun; 150():63-72. PubMed ID: 33892408
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
[TBL] [Abstract][Full Text] [Related]
28. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
[No Abstract] [Full Text] [Related]
29. A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab.
Gao R; Yang F; Yang C; Zhang Z; Liu M; Xiang C; Hu H; Luo X; Li J; Liu R
Front Immunol; 2023; 14():1114994. PubMed ID: 37426639
[TBL] [Abstract][Full Text] [Related]
30. Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor.
Wang W; Wang Q; Xu C; Li Z; Song Z; Zhang Y; Cai X; Zhang S; Lian B; Li W; Liu A; Zhan P; Liu H; Lv T; Miao L; Min L; Chen Y; Yuan J; Wang F; Jiang Z; Lin G; Pu X; Rao C; Lv D; Yu Z; Li X; Tang C; Zhou C; Xie C; Zhang J; Guo H; Chu Q; Meng R; Wu J; Zhang R; Wang L; Zhu Y; Hu X; Xie Y; Lin X; Cai J; Lan F; Feng H; Wang L; Yao W; Shi X; Huang J; Chen H; Zhang Y; Sun P; Wan B; Pang F; Xu Z; Wang K; Xia Y; Ye M; Wang D; Wei Q; Feng S; Zhou J; Zhang J; Lv D; Gao W; Kang J; Yu G; Liang X; Yu C; Shi L; Yang N; Wu L; Hong Z; Hong W; Fang M; Zhang Y; Lu Y; Wang G; Ma S; Si L; Fang W; Song Y
Thorac Cancer; 2022 Dec; 13(23):3420-3430. PubMed ID: 36268845
[TBL] [Abstract][Full Text] [Related]
31. Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.
Shu Y; Xu W; Su R; Ran P; Liu L; Zhang Z; Zhao J; Chao Z; Fu G
Front Immunol; 2023; 14():1251645. PubMed ID: 37799725
[TBL] [Abstract][Full Text] [Related]
32. Landscape of Immune-Related Pneumonitis in Cancer Patients with Asthma Being Treated with Immune Checkpoint Blockade.
Galant-Swafford J; Troesch A; Tran L; Weaver A; Doherty TA; Patel SP
Oncology; 2020; 98(2):123-130. PubMed ID: 31665718
[TBL] [Abstract][Full Text] [Related]
33. Radiation recall pneumonitis triggered by an immune checkpoint inhibitor following re-irradiation in a lung cancer patient: a case report.
Ye X; Yang J; Stebbing J; Peng L
BMC Pulm Med; 2022 Feb; 22(1):54. PubMed ID: 35123465
[TBL] [Abstract][Full Text] [Related]
34. A rare case of miliary tuberculosis in a patient with NSCLC receiving PD1 inhibitor therapy, mimicking autoimmune pneumonitis.
Nikola N; Natasa D; Milica K
J Cancer Res Ther; 2023 Jan; 19(Suppl 2):S909-S911. PubMed ID: 38384077
[TBL] [Abstract][Full Text] [Related]
35. Safety of immune checkpoint inhibitors in non-small-cell lung cancer patients with idiopathic interstitial pneumonia: a matched case-control study.
Ichimura T; Hinata M; Ichikura D; Suzuki S
Cancer Chemother Pharmacol; 2022 Jan; 89(1):21-30. PubMed ID: 34648059
[TBL] [Abstract][Full Text] [Related]
36. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
[TBL] [Abstract][Full Text] [Related]
37. Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis.
Zhou P; Zhao X; Wang G
Respiration; 2022; 101(11):1035-1050. PubMed ID: 36108598
[TBL] [Abstract][Full Text] [Related]
38. Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis.
Lin X; Deng J; Deng H; Yang Y; Sun N; Zhou M; Qin Y; Xie X; Li S; Zhong N; Song Y; Zhou C
Front Immunol; 2021; 12():818492. PubMed ID: 35095920
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis: A single-institution retrospective study.
Wang H; Zhao Y; Zhang X; Si X; Song P; Xiao Y; Yang X; Song L; Shi J; Zhao H; Zhang L
Cancer Med; 2021 Jan; 10(1):188-198. PubMed ID: 33211395
[TBL] [Abstract][Full Text] [Related]
40. Clinical course and prognosis of patients with lung cancer who develop anticancer therapy-related pneumonitis.
Matsubara T; Yamaguchi M; Jinnouchi M; Takamori S; Fujishita T; Toyozawa R; Ito K; Shimokawa M; Seto T; Okamoto T
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1857-1864. PubMed ID: 33387034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
